The Therapeutic Potential of Extracellular Vesicles Versus Mesenchymal Stem Cells in Liver Damage

Rostom, Dina M; Attia, Noha; Khalifa, Hoda; Nazel, Maha W Abou; Sabaawy, Eshrak A El

doi:10.1007/s13770-020-00267-3

Cited by 38 publications

(29 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance, many studies have shown that MSC-derived EVs retain the biological activity of parental MSCs. It has been demonstrated that EVs showed a similar therapeutic effect as MSCs in selected animal models [ 101 ]. However, different studies found various effective components of MSCs in specific animal models and human diseases, and the interactions and functional differences between effectors remain elusive.…”

Section: Challenges In Technology Transfer Of Mscs From Bench To Bedsmentioning

confidence: 99%

Challenges and advances in clinical applications of mesenchymal stromal cells

et al. 2021

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease.

show abstract

Section: Challenges In Technology Transfer Of Mscs From Bench To Bedsmentioning

confidence: 99%

Challenges and advances in clinical applications of mesenchymal stromal cells

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The paracrine mechanism is the secretion of soluble factors and the transmission of microvesicles containing proteins, mRNAs, genes and miRNAs. 23 One of the secreted factors is hepatic growth factor (HGF), which displays antiapoptotic activity in hepatocytes and acts as an important part in the regeneration of the liver. [24][25][26] In addition, the antifibrotic effects of MSCs can be a result of a combined set of mechanisms including modulation of immune system, inhibition of transforming growth factor-β (TGF-β) mediated differentiation of hepatic stellate cells (HSCs) into myofibroblasts, 25,27,28 oxidative stress inhibition, and matrix remodeling.…”

Section: Msc-based Cell Therapy For Lfmentioning

confidence: 99%

“…This mode of administration has revealed clinical effectiveness in different studies. 23 However, some studies reported that most of the intravenously administered MSCs settle in the lung microvasculature even in the absence of lung injury. In addition to the IV route, local infusion of MSCs into the portal vein comprises a convenient way for MSCs transplantation.…”

Section: Msc-based Cell Therapy For Lfmentioning

confidence: 99%

“…48 Similar findings were also demonstrated using murine BM-MSC-EVs on both histopathological and biochemical levels by down-regulating the expression of α-SMA. 23,49 Moreover, decrease in level of quantitative gene expression of TGF-β, collagen-1α, IL-1β was reported. 50 In a thioacetamide (TAA)-induced chronic LF model in mice, antifibrotic effects of EVs obtained from hESC-derived MSCs has been reported.…”

Section: Msc-evs-based Cell-free Therapy For Lfmentioning

confidence: 99%

“…22 Consequently, a conceptual shift has confirmed that MSCs enhance tissue repair mainly thru their paracrine factors, cell-to-cell communication or various types of extracellular vesicles (EVs). 23 Copyright 2020 KEI Journals. All Rights Reserved http://journals.ke-i.org/index.php/mra However, a major question remains to be answered: Is it possible to determine which approach is more effective for MSC therapy, cell-based or cell-free?…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mesenchymal stem cells versus their extracellular vesicles in treatment of liver fibrosis: Is it possible to compare?

Attia

Khalifa

Rostom

et al. 2021

MRAJ

Self Cite

View full text Add to dashboard Cite

Liver fibrosis (LF) is a worldwide health problem that is associated with a range of complications and high mortality. Due to the scarcity of liver donors, mesenchymal stem cell (MSC) therapy emerged as an alternative therapeutic strategy. However, it is widely accepted that most of the transplanted MSCs exhibit their therapeutic impact mainly via a bystander paracrine (medicinal) capacity. In addition to their secretory proteins, MSCs also produce various types of extracellular vesicles (EVs) that are classiﬁed into three main subtypes: microvesicles, exosomes and apoptotic bodies. Thanks to their peculiar cargo composition (e.g., proteins, lipids, and nucleic acids), EVs serve as an advantageous candidate for cell-free therapy. Recently, MSC-derived EVs (MSC-EVs) have gained the podium due to their regenerative and immunomodulatory effect. In mitigation/treatment of LF, a plethora of recent studies have shown the anti-inflammatory, anti-fibrotic and cytoprotective effects of both MSCs and MSC-EVs in various in vitro and in vivo models of LF. However, despite the limited evidence, we sought in this mini review to sort out the established data and formulate several challenging questions that must be answered to pave the way for further clinical applications. One of the major questions to ask is “Which is the best therapeutic approach, MSCs or MSC-EVs?” We tried to highlight how difficult it might be to compare the two approaches while our understanding of both candidates is still deficient. Among the major obstacles against such comparison is the inaccurate equivalent dose determination, the unknown in vivo behavior, and the undetermined lifespan/fate of each. Currently, the fields of MSCs and MSC-EVs seem to be rich in ideas but lacking in appropriate technologies to test these ideas. Nevertheless, continuous efforts are likely to help resolve some of the challenges listed here.

show abstract

Harnessing Engineered Extracellular Vesicles from Mesenchymal Stem Cells as Therapeutic Scaffolds for Bone‐Related Diseases

Yu,

Wang,

Zhou

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) play a crucial role in maintaining bone homeostasis and are extensively explored for cell therapy in various bone‐related diseases. In addition to direct cell therapy, the secretion of extracellular vesicles (EVs) by MSCs has emerged as a promising alternative approach. MSC‐derived EVs (MSC‐EVs) offer equivalent therapeutic efficacy to MSCs while mitigating potential risks. These EVs possess unique properties that enable them to traverse biological barriers and deliver bioactive cargos to target cells. Furthermore, by employing modification and engineering strategies, the therapeutic effects and tissue targeting specificity of MSC‐EVs can be further enhanced to meet specific therapeutic needs. In this review, the mechanisms and advantages of MSC‐EV therapy in diseased bone tissues are highlighted. Through simple isolation and modification techniques, MSC‐EV‐based biomaterials have demonstrated great promise for bone regeneration. Finally, future perspectives on MSC‐EV therapy are presented, envisioning the development of next‐generation regenerative materials and bioactive agents for clinical translation in the field of bone regeneration.

show abstract

The Therapeutic Potential of Extracellular Vesicles Versus Mesenchymal Stem Cells in Liver Damage

Cited by 38 publications

References 51 publications

Challenges and advances in clinical applications of mesenchymal stromal cells

Challenges and advances in clinical applications of mesenchymal stromal cells

Mesenchymal stem cells versus their extracellular vesicles in treatment of liver fibrosis: Is it possible to compare?

Harnessing Engineered Extracellular Vesicles from Mesenchymal Stem Cells as Therapeutic Scaffolds for Bone‐Related Diseases

Contact Info

Product

Resources

About